PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Nurmohamed, Michael T.
TI  - Anti-TNF Therapy and CV Risk in RA
DP  - 2012 Sep 01
TA  - MD Conference Express
PG  - 12--13
VI  - 12
IP  - 9
4099  - http://mdc.sagepub.com/content/12/9/12.short
4100  - http://mdc.sagepub.com/content/12/9/12.full
AB  - Systemic inflammation in patients with rheumatoid arthritis (RA) leads to a greater risk of cardiovascular (CV) events that are linked to tumor necrosis factor (TNF)-related atherogenesis. Anti-TNF therapies have been shown in observational studies to reduce the risk of CV events in patients with RA. The objective of this retrospective medical record review was to compare the effect of exposure to anti-TNF treatment on the risk of CV events in patients with RA with those who were treated with methotrexate and other disease-modifying therapies.